logo
  

Seelos To Use Aptar Pharma's Bidose Liquid System Device With SLS-002 Program

Seelos Therapeutics, Inc. (SEEL) has signed an agreement with AptarGroup, Inc. (ATR) for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and Post-Traumatic Stress Disorder.

Aptar's patented BDS Liquid System has been approved by the FDA and European Medicines Agency for the delivery of other therapeutics.

Raj Mehra, Chairman and CEO of Seelos, said: "This partnership strengthens the collaboration between Seelos and Aptar, and further protects the SLS-002 franchise."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant PepsiCo Inc. reported Thursday sharply lower profit in its fourth quarter, despite higher revenues. Adjusted earnings and top line beat market estimates. Further, the company lifted its dividend and announced around $1 billion share buyback. Looking ahead for fiscal 2023, PepsiCo expects growth in organic revenues and core earnings, which is below current market estimates. Shares of Credit Suisse Group AG were losing around 9 percent in the morning trading in Switzerland as well as in pre-market activity on the NYSE after the banking major said it sees substantial loss before taxes in fiscal 2023 after reporting narrower loss in its fourth quarter with lower expenses, despite weak revenues. Walt Disney Co. announced plans to cut 7,000 jobs worldwide as part of its restructuring efforts to save billions in costs. The planned layoffs represent around 3.6 percent of Disney's global workforce. Chief Executive Officer Bob Iger, during the company's first-quarter earnings call, said the restructuring would help the firm save $5.5 billion in costs.
RELATED NEWS
Follow RTT